Labelling of subpleural pulmonary nodules with blue dye and contrast agents under CT-guided control and subsequent video-assisted thoracoscopic resection: the BLUEPAT prospective randomised study
A trial will test whether dye-marking helps surgeons remove small lung nodules less invasively, addressing a real clinical diagnostic challenge.
The BLUEPAT trial protocol describes a 72-participant randomized study evaluating CT-guided color marking of subpleural lung nodules with Patent Blue V and iohexol prior to video-assisted thoracoscopic resection, extending breast cancer sentinel node technology to pulmonary indications. As a protocol-only publication, no efficacy data are available; the approach addresses a relevant clinical need for minimally invasive diagnosis of small lung nodules.
What the study was
- Study design
- Prospective randomized controlled trial protocol
- Population
- Patients with subpleural lung nodules requiring histological diagnosis (n=72 planned); randomized 1:1
- Sample size
- 72
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Trials
Why it surfaced
Trial protocol only; no results data; approach is procedural rather than molecular; limited direct connection to liquid biopsy/ctDNA watchlist topic.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.